Get the Stockscreener App
0.4407
2.07%
-0.0093
Applied Therapeutics Inc stock is traded at $0.4407, with a volume of 673.52K.
It is down -2.07% in the last 24 hours and up +37.72% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.45
Open:
$0.46
24h Volume:
673.52K
Relative Volume:
0.32
Market Cap:
$62.39M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.3264
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
-8.19%
1M Performance:
+37.72%
6M Performance:
-24.86%
1Y Performance:
-92.21%
1-Day Range:
$0.4301
$0.46
1-Week Range:
$0.4011
$0.5367
52-Week Range:
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.4407 | 63.71M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
What makes Applied Therapeutics Inc. stock price move sharplyEarnings Report Entry Points For Fast Growth - jammulinksnews.com
Brokerages Set Applied Therapeutics Inc. (NASDAQ:APLT) PT at $6.10 - MarketBeat
What is the dividend policy of Applied Therapeutics Inc. stockValue Investing Picks For Every Investor - jammulinksnews.com
Applied Therapeutics (APLT) Projected to Post Earnings on Wednesday - MarketBeat
Is Applied Therapeutics Inc. still worth holding after the dipBuy Alerts With Low Risk Confirmation Noted - metal.it
How volatile is Applied Therapeutics Inc. stock compared to the marketDaily Trading Outlook With Proven Results - jammulinksnews.com
Wall Street Zen Upgrades Applied Therapeutics (NASDAQ:APLT) to Sell - MarketBeat
Published on: 2025-07-29 13:58:52 - metal.it
Why Applied Therapeutics Inc. stock attracts strong analyst attentionLow Capital High Return Stock Plans Reviewed - metal.it
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
What catalysts could drive Applied Therapeutics Inc. stock higher in 2025Capitalize on proven investment strategies - jammulinksnews.com
What are analysts’ price targets for Applied Therapeutics Inc. in the next 12 monthsExponential return rates - jammulinksnews.com
How does Applied Therapeutics Inc. compare to its industry peersRemarkable growth - jammulinksnews.com
What institutional investors are buying Applied Therapeutics Inc. stockConsistent wealth multiplication - jammulinksnews.com
What are the latest earnings results for Applied Therapeutics Inc.Consistent triple-digit returns - jammulinksnews.com
What is Applied Therapeutics Inc. company’s growth strategyMaximize your portfolio’s growth potential - jammulinksnews.com
Published on: 2025-07-28 02:44:29 - jammulinksnews.com
Applied Therapeutics (NASDAQ:APLT) Shares Down 5%Here's Why - MarketBeat
Is Applied Therapeutics Inc. a good long term investmentFree Consultation - PrintWeekIndia
Should I buy Applied Therapeutics Inc. stock before earningsFree Investment Risk Control - jammulinksnews.com
What drives Applied Therapeutics Inc. stock priceFastest-growing stock picks - Autocar Professional
What analysts say about Applied Therapeutics Inc. stockUnbelievable profit margins - PrintWeekIndia
Applied Therapeutics Inc. Stock Analysis and ForecastFree Stock Selection - Autocar Professional
How Applied Therapeutics Inc. stock reacts to Fed policy changesTop Analyst Picks - Newser
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics LawsuitAPLT - ACCESS Newswire
Applied Therapeutics, Inc. shares rise 1.28% premarket after Intesa Sanpaolo invests in NUCLIDIUM's cancer radiotheranostics. - AInvest
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Applied Therapeutics Inc Stock (APLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
| Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
| Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
| Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
| Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
| Funtleyder Leslie D. | Chief Financial Officer |
Aug 22 '24 |
Sale |
5.83 |
13,530 |
78,880 |
277,911 |
| Perfetti Riccardo | Chief Medical Officer |
Aug 22 '24 |
Sale |
5.83 |
22,681 |
132,230 |
986,853 |
| Shendelman Shoshana | President and CEO |
Aug 13 '24 |
Sale |
6.18 |
357,423 |
2,208,874 |
4,810,430 |
| Shendelman Shoshana | President and CEO |
Aug 12 '24 |
Sale |
5.98 |
300,000 |
1,794,000 |
5,167,853 |
| Shendelman Shoshana | President and CEO |
Aug 14 '24 |
Sale |
5.93 |
119,591 |
709,175 |
4,690,839 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):